{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:09:35Z","timestamp":1773932975366,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:45:23Z","timestamp":1763660723000},"page":"125.e23-125.e31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3906-6011","authenticated-orcid":false,"given":"Alexa Rose","family":"Le\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Risk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinn-ing","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Jarrard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-6413","authenticated-orcid":false,"given":"Kyle A.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.11.004_bib0001","unstructured":"Cancer of the prostate\u2014cancer stat facts. (n.d.). Seer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html Accessed August 1, 2025."},{"issue":"8","key":"10.1016\/j.urolonc.2025.11.004_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5306\/wjco.v11.i8.573","article-title":"Statins in risk-reduction and treatment of cancer","volume":"11","author":"Barbalata","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.11.004_bib0003","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.1007\/s11033-020-05918-1","article-title":"Rosuvastatin inhibit spheroid formation and epithelial-mesenchymal transition (EMT) in prostate cancer PC-3 cell line","volume":"47","author":"Deezagi","year":"2020","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.004_bib0004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jcpt.13092","article-title":"The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone\/enzalutamide: a systematic review and meta-analysis","volume":"45","author":"Yang","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.urolonc.2025.11.004_bib0005","first-page":"484","article-title":"Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis","volume":"74","author":"Aydh","year":"2021","journal-title":"Cent European J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.11.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42676","article-title":"Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Jayalath","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.urolonc.2025.11.004_bib0007","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/ph15020131","article-title":"The effects of statins on prostate cancer patients receiving androgen deprivation therapy or definitive Therapy: a systematic review and meta-analysis","volume":"15","author":"Hou","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2025.11.004_bib0008","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2020.12.031","article-title":"The Association Between Statin Use and Outcomes in patients initiating androgen deprivation therapy","volume":"79","author":"Hamilton","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0009","series-title":"drug utilization annual report, veterans affairs pharmacy benefits management services","year":"2016"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12874-015-0047-5","article-title":"Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods","volume":"15","author":"Aly","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.004_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2013.49.4757","article-title":"Use of statins and the risk of death in patients with prostate cancer","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0012","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2014.08.102","article-title":"Increasing use of observation among men at low risk for prostate cancer mortality","volume":"193","author":"Ritch","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0013","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0014","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0015","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/sim.3402","article-title":"Analyses of cumulative incidence functions via non-parametric multiple imputation","volume":"27","author":"Ruan","year":"2008","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.urolonc.2025.11.004_bib0016","first-page":"2054","article-title":"Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1","volume":"54","author":"Gao","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.urology.2024.08.059","article-title":"Statin concentration in prostatic tissue is subtype- and dose-dependent","volume":"194","author":"Chavarriaga","year":"2024","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.urolonc.2025.11.004_bib0018","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/pros.23863","article-title":"Access and concentrations of atorvastatin in the prostate in men with prostate cancer","volume":"79","author":"Knuuttila","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9275466","article-title":"Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: a systematic review and meta-analysis of cohort studies","volume":"2022","author":"An","year":"2022","journal-title":"J Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.11.004_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/COC.0000000000001012","article-title":"Association between Statin exposure and incidence and prognosis of prostate cancer: a meta-analysis based on observational studies","volume":"46","author":"Cao","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL, and Prosper","volume":"140","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0022","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2022.03.042","article-title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: secondary analysis of COU-AA-301 and COU-AA-302","volume":"170","author":"Wilson","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.11.004_bib0023","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1055-9965.EPI-21-1165","article-title":"The association of prediagnostic statin use with aggressive prostate cancer from the multiethnic cohort study","volume":"31","author":"Chen","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.urolonc.2025.11.004_bib0024","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41391-021-00475-5","article-title":"Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US veterans with advanced prostate cancer","volume":"25","author":"Khan","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.urolonc.2025.11.004_bib0025","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/pros.24557","article-title":"Post-diagnostic metformin and statin use and risk of biochemical recurrence in veterans diagnosed with prostate cancer","volume":"83","author":"Khan","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0026","article-title":"Statin use and the risk of prostate cancer biochemical recurrence following definitive therapy: a systematic review and meta-analysis of cohort studies","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028513","article-title":"The association of statin use and biochemical recurrence after curative treatment for prostate cancer: a systematic review and meta-analysis","volume":"101","author":"Yin","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"18","key":"10.1016\/j.urolonc.2025.11.004_bib0028","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1158\/1078-0432.CCR-21-0480","article-title":"Adjuvant low-dose statin use after radical prostatectomy: the PRO-STAT randomized clinical trial","volume":"27","author":"Jeong","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.11.004_bib0029","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin versus placebo for prostate cancer before radical prostatectomy\u2014a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Murtola","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.11.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7827821","article-title":"Association of statin use with the risk of incident prostate cancer: a meta-analysis and systematic review","volume":"2022","author":"Xu","year":"2022","journal-title":"J Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2025.11.004_bib0031","doi-asserted-by":"crossref","first-page":"7399","DOI":"10.1002\/cam4.2500","article-title":"Association of statin use with risk of Gleason score-specific prostate cancer: a hospital-based cohort study","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.004_bib0032","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.euf.2020.06.005","article-title":"The suggested unique association between the various statin subgroups and prostate cancer","volume":"7","author":"Goldberg","year":"2021","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:40:48Z","timestamp":1773924048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004508"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}